Polarized immune responses differentially regulate cancer development

Immunological Reviews

Volumn 222, Issue 1, 2008, Pages 145-154

  Johansson, Magnus ^a   DeNardo, David G ^a   Coussens, Lisa M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adaptive immunity; Cancer; Humoral immunity; Inflammation; Innate immunity; Leukocytes

Indexed keywords

MELANOMA VACCINE;

ADAPTIVE IMMUNITY; ANTIGEN ANTIBODY COMPLEX; CANCER GROWTH; HELPER CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; INNATE IMMUNITY; LEUKOCYTE; MELANOMA; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY;

ANIMALS; CELL LINEAGE; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, INNATE; INFLAMMATION; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RATS; RECEPTORS, FC; SUPPRESSOR FACTORS, IMMUNOLOGIC; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TOLL-LIKE RECEPTORS;

EID: 41149136843     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2008.00600.x     Document Type: Review

References (93)

1. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer 2001 1 : 46 54.
2. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002 420 : 860 867.
3. Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004 4 : 839 849.
4. Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu Rev Pathol Mech Dis 2006 1 : 119 150.
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000 100 : 57 70.
6. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001 357 : 539 545.
7. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005 7 : 211 217.
8. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006 6 : 24 37.
9. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005 5 : 263 274.
10. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004 21 : 137 148.
11. Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 2006 124 : 823 835.
12. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005 5 : 749 759.
13. Tan T, Coussens LM. Humoral immunity, inflammation and cancer. Curr Opin Immunol 2007 19 : 209 216.
14. Colombo MP, Piconese S. Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer 2007 7 : 880 887.
15. Dalgleish AG, O'Byrne KJ. Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer. Adv Cancer Res 2002 84 : 231 276.
16. Agarwal A, Verma S, Burra U, Murthy NS, Mohanty NK, Saxena S. Flow cytometric analysis of Th1 and Th2 cytokines in PBMCs as a parameter of immunological dysfunction in patients of superficial transitional cell carcinoma of bladder. Cancer Immunol Immunother 2006 55 : 734 743.
17. Kanazawa M, et al. Effects of PSK on T and dendritic cells differentiation in gastric or colorectal cancer patients. Anticancer Res 2005 25 : 443 449.
18. Sheu BC, Lin RH, Lien HC, Ho HN, Hsu SM, Huang SC. Predominant Th2/Tc2 polarity of tumor-infiltrating lymphocytes in human cervical cancer. J Immunol 2001 167 : 2972 2978.
19. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002 3 : 991 998.
20. Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 2007 5 : 505 517.
21. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006 124 : 783 801.
22. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2001 2 : 612 619.
23. Proietti E, et al. Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J Immunol 2002 169 : 375 383.
24. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006 24 : 677 688.
25. Dunn GP, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol 2005 6 : 722 729.
26. Lighvani AA, et al. T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells. Proc Natl Acad Sci USA 2001 98 : 15137 15142.
27. Szabo SJ, Jacobson NG, Dighe AS, Gubler U, Murphy KM. Developmental commitment to the Th2 lineage by extinction of IL-12 signaling. Immunity 1995 2 : 665 675.
28. Dinarello CA. IL-18: a TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol 1999 103 : 11 24.
29. Yang J, Murphy TL, Ouyang W, Murphy KM. Induction of interferon-gamma production in Th1 CD4+T cells: evidence for two distinct pathways for promoter activation. Eur J Immunol 1999 29 : 548 555.
30. Lee NA, Gelfand EW, Lee JJ. Pulmonary T cells and eosinophils: coconspirators or independent triggers of allergic respiratory pathology? J Allergy Clin Immunol 2001 107 : 945 957.
31. Reiner SL. Epigenetic control in the immune response. Hum Mol Genet 2005 14 : R41 R46.
32. Ouyang W, et al. Stat6-independent GATA-3 autoactivation directs IL-4-independent Th2 development and commitment. Immunity 2000 12 : 27 37.
33. Cua DJ, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003 421 : 744 748.
34. Bettelli E, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006 441 : 235 238.
35. Annunziato F, et al. Phenotypic and functional features of human Th17 cells. J Exp Med 2007 204 : 1849 1861.
36. Langowski JL, et al. IL-23 promotes tumour incidence and growth. Nature 2006 442 : 461 465.
37. Fehervari Z, Sakaguchi S. CD4+Tregs and immune control. J Clin Invest 2004 114 : 1209 1217.
38. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999 59 : 3128 3133.
39. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999 163 : 5211 5218.
40. Curiel TJ, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004 10 : 942 949.
41. Delves PJ, Roitt IM. The immune system. Second of two parts. N Engl J Med 2000 343 : 108 117.
42. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005 54 : 721 728.
43. Alegre ML, Frauwirth KA, Thompson CB. T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 2001 1 : 220 228.
44. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001 2 : 675 680.
45. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004 4 : 499 511.
46. Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 2006 124 : 849 863.
47. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007 117 : 1184 1194.
48. Apetoh L, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007 13 : 1050 1059.
49. Janssens S, Beyaert R. A universal role for MyD88 in TLR/IL-1R-mediated signaling. Trends Biochem Sci 2002 27 : 474 482.
50. Rakoff-Nahoum S, Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 2007 317 : 124 127.
51. Naugler WE, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007 317 : 121 124.
52. Yang R, et al. B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88. J Immunol 2005 174 : 7912 7919.
53. Rifkin IR, Leadbetter EA, Busconi L, Viglianti G, Marshak-Rothstein A. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 2005 204 : 27 42.
54. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006 6 : 823 835.
55. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993 73 : 161 195.
56. Hayen W, Goebeler M, Kumar S, Riessen R, Nehls V. Hyaluronan stimulates tumor cell migration by modulating the fibrin fiber architecture. J Cell Sci 1999 112 : 2241 2251.
57. Chapoval AI, Fuller JA, Kremlev SG, Kamdar SJ, Evans R. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells. J Immunol 1998 161 : 6977 6984.
58. Barbera-Guillem E, et al. B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion. Cancer Immunol Immunother 2000 48 : 541 549.
59. Perricone MA, et al. Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes. J Immunother 2004 27 : 273 281.
60. Shah S, et al. Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int J Cancer 2005 117 : 574 586.
61. Abu-Shakra M, Buskila D, Ehrenfeld M, Conrad K, Shoenfeld Y. Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis 2001 60 : 433 441.
62. Gumus E, Erdamar S, Demirel G, Horasanli K, Kendirci M, Miroglu C. Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients. Int J Urol 2004 11 : 1070 1077.
63. Schreiber H, Wu TH, Nachman J, Rowley DA. Immunological enhancement of primary tumor development and its prevention. Semin Cancer Biol 2000 10 : 351 357.
64. Barbera-Guillem E, May KF, Jr., Nyhus JK, Nelson MB. Promotion of tumor invasion by cooperation of granulocytes and macrophages activated by anti-tumor antibodies. Neoplasia 1999 1 : 453 460.
65. Aziz M, Das TK, Rattan A. Role of circulating immune complexes in prognostic evaluation and management of genitourinary cancer patients. Indian J Cancer 1997 34 : 111 120.
66. Das TK, Aziz M, Rattan A, Sherwani R. Prognostic significance of circulating immune complexes in malignant tumours of head and neck. J Indian Med Assoc 1995 93 : 3 7.
67. Dass TK, Aziz M, Rattan A, Tyagi SP. Clinical utility and monitoring of breast cancer by circulating immune complexes. Indian J Pathol Microbiol 1992 35 : 298 307.
68. Takai T. Fc receptors and their role in immune regulation and autoimmunity. J Clin Immunol 2005 25 : 1 18.
69. Aurora AB, et al. Immune complex-dependent remodeling of the airway vasculature in response to a chronic bacterial infection. J Immunol 2005 175 : 6319 6326.
70. Coussens LM, Hanahan D, Arbeit JM. Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. Am J Path 1996 149 : 1899 1917.
71. de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005 7 : 411 423.
72. Barbera-Guillem E, Nyhus JK, Wolford CC, Friece CR, Sampsel JW. Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. Cancer Res 2002 62 : 7042 7049.
73. Schmidt RE, Gessner JE. Fc receptors and their interaction with complement in autoimmunity. Immunol Lett 2005 100 : 56 67.
74. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 2005 310 : 1510 1512.
75. Nimmerjahn F, Ravetch JV. Antibodies, Fc receptors and cancer. Curr Opin Immunol 2007 19 : 239 245.
76. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006 313 : 670 673.
77. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006 6 : 715 727.
78. Galon J, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006 313 : 1960 1964.
79. Coca S, et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 1997 79 : 2320 2328.
80. Smyth MJ, Crowe NY, Godfrey DI. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol 2001 13 : 459 463.
81. Hayakawa Y, et al. IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide. Blood 2002 100 : 1728 1733.
82. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003 3 : 666 675.
83. Almand B, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000 6 : 1755 1766.
84. Serafini P, et al. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother 2004 53 : 64 72.
85. Zea AH, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005 65 : 3044 3048.
86. Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+myeloid cells. J Immunol 2001 166 : 5398 5406.
87. Chen ML, et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci USA 2005 102 : 419 424.
88. Yang L, et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004 6 : 409 421.
89. Martin F, Chan AC. B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol 2006 24 : 467 496.
90. Johansson M, Tan T, de Visser KE, Coussens LM. Immune cells as anti-cancer therapeutic targets and tools. J Cell Biochem 2007 101 : 918 926.
91. Silverman GJ. Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms. Arthritis Rheum 2006 54 : 2356 2367.
92. Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006 6 : 394 403.
93. Gokbuget N, Hoelzer D. Novel antibody-based therapy for acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2006 19 : 701 713.